Table 1.
The demographic and comorbid medical disorders at index date, before and after propensity score weighting, among hypertensive and diabetic patients who were prescribed with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)
| Propensity score weighting | ||||||
|---|---|---|---|---|---|---|
| Before | After | |||||
| ACEi (n = 6898) | ARB (n = 12,758) | Standardized mean difference | ACEi (n = 6898) | ARB (n = 12,758) | Standardized mean difference | |
| Duration from DM to index datea (years) | 3.07 ± 3.15 | 3.69 ± 3.33 | −0.1931 | 3.17 ± 3.15 | 3.08 ± 2.26 | −0.0032 |
| Age (years) (mean ± SD) | 61.5 ± 13.0 | 62.4 ± 12.8 | −0.0711 | 61.5 ± 13.0 | 61.3 ± 9.7 | 0.0183 |
| Age group | 0.0944 | 0.0053 | ||||
| 20–49 (%) | 20.9 | 17.2 | 20.9 | 21.0 | ||
| 50–64 (%) | 39.4 | 40.3 | 39.4 | 39.5 | ||
| 65+ (%) | 39.7 | 42.4 | 39.7 | 39.5 | ||
| Male sex | 59.5 % | 53.1 % | 0.1271 | 59.5 % | 59.5 % | −0.0016 |
| Congestive heart failure | 4.51 % | 4.85 % | −0.0163 | 4.51 % | 4.51 % | −0.0000 |
| Stroke | 12.73 % | 14.70 % | −0.0572 | 12.73 % | 12.73 % | −0.0000 |
| Malignant dysrhythmia | 0.45 % | 0.49 % | −0.0054 | 0.45 % | 0.45 % | 0.0004 |
| Cardiogenic shock | 0.32 % | 0.23 % | 0.0176 | 0.32 % | 0.33 % | −0.0025 |
| MI/PCI | 5.00 % | 4.56 % | 0.0206 | 5.00 % | 4.98 % | 0.0010 |
| CABG | 0.46 % | 0.60 % | −0.0192 | 0.46 % | 0.46 % | 0.0012 |
| Thrombolysis therapy | 0.25 % | 0.24 % | 0.0023 | 0.25 % | 0.24 % | 0.0018 |
| Hyperlipidemia | 54.54 % | 59.81 % | −0.1066 | 54.54 % | 54.68 % | −0.0029 |
| Chronic kidney disease | 13.51 % | 16.73 % | −0.0901 | 13.51 % | 13.51 % | 0.0001 |
DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MI myocardial infarction, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery
aIndex date was the date first prescribed either ACEi or ARB